Company Overview and News

3 Stocks Set to Beat Q1 Earnings Estimates

51m investorplace
Stocks opened slightly higher on Wednesday as investors begin to reap some rewards from the start of first quarter earnings season. Despite this recent market momentum, uncertainty is still present, which means investors need to continue to utilize Q1 earnings season in order to look for stocks set to top earnings estimates.

The Zacks Analyst Blog Highlights: UnitedHealth, Netflix, Caterpillar, M&T Bank and Infosys

1h zacks
Chicago, IL – April 19, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include UnitedHealth (UNH - Free Report) , Netflix (NFLX - Free Report) , Caterpillar (CAT - Free Report) , M&T Bank (MTB - Free Report) and Infosys (INFY - Free Report) .

2018 Q1 Hedge Fund Letters – UPDATED 4/17 Pabrai, Locus Wood, Active-Passive, $$ & More

2h archive.mlgngo
Want market-beating yield in today's zero-interest world? The right dividend stocks could boost your returns 345%.

U.S. first-time unemployment claims dip to 232,000

2h feeds.marketwatch
The total value of bonds in the lowest rung of the high-grade universe is bigger than the output of the world’s fifth-largest economy. Its growth is raising alarm bells for some analysts. Full Story

Manole Capital: 2nd Quarter 2018 Newsletter

2h seekingalpha
During the chaos of the Financial Crisis, the S&P 500 bottomed out at 677 on March 9, 2009. On that day, there was no signal or “all clear sign” that indicated it was safe to re-enter the market. Quite the contrary, it was hectic and filled with uncertainty. Nine years later, with the S&P 500 above 2,500, the market generates a return of over 250%.

Sky reports strong quarter before bid battle steps up

4h channelnewsasia
Sky , the pay-TV group at the center of a takeover battle between Fox, Disney and Comcast, reported a strong third quarter on Thursday, underlining its appeal to rival U.S. entertainment groups who want to expand in Europe.

Sky reports strong quarter before bid battle steps up

4h reuters
LONDON (Reuters) - Sky (SKYB.L), the pay-TV group at the center of a takeover battle between Fox, Disney and Comcast, reported a strong third quarter on Thursday, underlining its appeal to rival U.S. entertainment groups who want to expand in Europe.

U.S. stock futures search for a catalyst as earnings stay in focus - MarketWatch

6h marketwatch
U.S. stock-index futures pointed to a roughly flat open Thursday, putting the main gauges on track for a second-straight day of muted action.

Assessing Value In The Digital Economy

If the goal is to assess corporate value in the new digital economy, the answer is "yes," because business models have changed so much since valuation practices began in the industrial era. In 2015, Tom Goodwin, executive vice president and head of innovation at Zenith USA, summed up the strangeness of the new economy when he said, "Uber (UBER), the world's largest taxi company, owns no vehicles. Facebook (NASDAQ:FB), the world's most popular media owner, creates no content.

PRESS DIGEST-New York Times business news - April 19

9h reuters
April 19 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

Weekly Edge: Earnings Season Is Upon Us

9h seekingalpha
Companies in the United States - among them, Netflix (NASDAQ:NFLX), Goldman Sachs (NYSE:GS), and UnitedHealth Group (NYSE:UNH) -have begun reporting their earnings for the first quarter of 2018, and the results have been strong so far. According to MarketWatch, earnings growth is expected to be 17.3% for S&P components, which is the fastest rate of expansion since 2011. The Wall Street Journal noted that 74% of the 43 companies that have reported earnings beat expectations.

UPDATE 1-At last minute, AT&T withdraws planned IPO of its Vrio Corp unit

14h reuters
April 18 (Reuters) - AT&T Inc has withdrawn its planned initial public offering of Vrio Corp, its DirecTV business in Latin America, just hours before the new stock was to start trading.

Earnings Watchlist

15h seekingalpha
In my last Monday Musings post, I shared 5 tips to help have a successful earnings season as an investor. Now, I wanted to share my specific watchlist that I have researched thoroughly and am anxiously waiting to possibly add to my portfolio.

AT&T unit Vrio postpones IPO - source

16h reuters
(Reuters) - The initial public offering of Vrio Corp, AT&T Inc’s (T.N) DirecTV business in Latin America, has been postponed, a source familiar with the matter said on Wednesday.

Top Stock Reports for UnitedHealth, Netflix & Caterpillar

16h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Netflix (NFLX) and Caterpillar (CAT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 64110L106